Jae Soo Shin, Ph. D., Managing Director of Il-Yang Pharm. Co. Ltd. Korea
Mr. Shin is a pharmacist and also holds a Ph.D. in Pharmacology from Seoul National University in Korea and is currently an adjunct professor at KonKuk University Medical School. He had worked as a chief of pharmacology & toxicology Lab. in the preclinical development of new drugs in Chong Kun Dang Pharmaceutical Corp. for 21 years. Since 2008, he has been working as a managing director for IL-YANG Pharm. Co. Ltd., being responsible for preclinical and clinical development of new drugs and several vaccines for human and avian influenza. Since 2013, he has also been a member of policy advisory committee of KSAP (The Korean Society of Applied Pharmacology).
Heon Ju Lee, Ph.D.
Dr. Lee holds Bachelor’s and Master’s degrees in Microbiology from Seoul National University in Korea and a Ph.D. in Environmental Toxicology from Hankuk University of Foreign Studies. For 29 years, he worked on the development of biopharmaceuticals in CJ Inc. and Samsung Group; and conducted nonclinical animal testing and licensing work for drug development in Korea Institute of Toxicology. Currently, he is the vice-president of BiocurePharm, leading the pre-clinical and clinical development of biopharmaceuticals such as interferon beta and CAR-T immune cell therapy products.
Since 2011, he has been a member of the Institutional Review Board (IRB) and a Certified Toxicology Professional in Korea.
Hyun Soo Lee, Ph.D.
Dr. Lee holds a Ph.D. in molecular biotechnology form Korea Advanced Institute of Science and Technology in Korea.
He has worked as a senior researcher in charge of the development of a variety of biopharmaceuticals in CJ Inc. (1987 ~ 2005), and as Director of research institute of JW Creagene Inc. (2005 ~ 2012) developing immune-cell therapies.
He is currently Director of research institute of Pharos Vaccine Inc. and a non-executive director of Aprogen Inc.